More plan sponsors are considering alternative PBMs that offer a lowest-net-cost approach that includes a more affordable yet clinically effective drug mix. (Photo: Shutterstock)
As we near the end of the second pandemic year, the desire for quality and affordable health care has never been more top of mind.
The pandemic raised new concerns about medication access and supply, both of which drove utilization and costs upward. Centers for Medicare & Medicaid Services (CMS) projects prescription spend for commercial plans will grow an average of 5% annually, meanwhile, plan sponsors continue to battle budget pressures and ambiguity over their spend. And the benefit needs of member populations have changed because of the pandemic, once again putting pharmacy benefits under the microscope for 2022.
David Fields is president & CEO at Navitus Health Solutions. He is responsible for external relationships such as industry thought-leader engagement, media interaction, and potential and current client strategies and support. David collaborates with the executive management team to maintain Navitus' strategic plan and to develop and direct its goals, policies and execution. Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
